Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: December 7, 2004
Last updated: November 16, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||April 2006 (Final data collection date for primary outcome measure)|
Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2005 Jun 15;79(11):1553-60.